Lifecore Biomedical, Inc. (LFCR) 10-Year Financial Performance & Capital Metrics

LFCR • • Industrial / General

HealthcareSpecialty & Generic PharmaContract Manufacturing & APICDMO Services

AboutLifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.Show more

Revenue $129M +0.5%
EBITDA -$9M -992.2%
Net Income -$39M -422.3%
EPS (Diluted) -1.27 -484.8%
Gross Margin 31.27% -4.2%
EBITDA Margin -7.15% -987.1%
Operating Margin -13.38% -94.1%
Net Margin -30.04% -420.8%
ROE -612.08% -280.5%
ROIC -9.94% -69.1%
Debt/Equity 97.92 +729.5%
Interest Coverage -0.79 -61.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 5.0% through buybacks

✗Weaknesses

✗High debt to equity ratio of 97.9x
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Expensive at 211.1x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-13.34%

5Y-4.24%

3Y5.02%

TTM5.31%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-596.83%

EPS CAGR

10Y-

5Y-

3Y-

TTM-1875.5%

ROCE

10Y Avg-4.01%

5Y Avg-6.64%

3Y Avg-8.73%

Latest-8.13%

Peer Comparison

CDMO Services

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
LFCRLifecore Biomedical, Inc.	303.48M	8.10	-6.38	0.47%	-24.01%	-88.29%		97.92
EVOEvotec SE	1.29B	3.62	-6.46	1.99%	-21.02%	-19.87%		0.47

Profit & Loss

	May 2016	May 2017	May 2018	May 2019	May 2020	May 2021	May 2022	May 2023	May 2024	May 2025
Sales/Revenue+	541.1M	532.26M	524.23M	557.56M	160.07M	100.87M	111.27M	103.27M	128.26M	128.87M
Revenue Growth %	0%	-0.02%	-0.02%	0.06%	-0.71%	-0.37%	0.1%	-0.07%	0.24%	0%
Cost of Goods Sold+	470.14M	449.07M	445.89M	476.56M	120.68M	61.94M	72.2M	75.28M	86.41M	88.57M
COGS % of Revenue	0.87%	0.84%	0.85%	0.85%	0.75%	0.61%	0.65%	0.73%	0.67%	0.69%
Gross Profit+	70.96M	83.19M	78.34M	81M	39.39M	38.94M	39.07M	27.98M	41.85M	40.3M
Gross Margin %	0.13%	0.16%	0.15%	0.15%	0.25%	0.39%	0.35%	0.27%	0.33%	0.31%
Gross Profit Growth %	0.08%	0.17%	-0.06%	0.03%	-0.51%	-0.01%	0%	-0.28%	0.5%	-0.04%
Operating Expenses+	56.74M	67.68M	64.75M	75.53M	65.26M	47.76M	50.86M	49.78M	50.69M	57.54M
OpEx % of Revenue	0.1%	0.13%	0.12%	0.14%	0.41%	0.47%	0.46%	0.48%	0.4%	0.45%
Selling, General & Admin	49.52M	58.21M	51.95M	64.06M	40.67M	27.72M	34.66M	38.97M	40.46M	44.05M
SG&A % of Revenue	0.09%	0.11%	0.1%	0.11%	0.25%	0.27%	0.31%	0.38%	0.32%	0.34%
Research & Development	7.23M	9.47M	12.8M	11.47M	7.58M	6.68M	7.84M	8.74M	8.57M	8.26M
R&D % of Revenue	0.01%	0.02%	0.02%	0.02%	0.05%	0.07%	0.07%	0.08%	0.07%	0.06%
Other Operating Expenses	0	-333K	0	0	17.01M	13.36M	8.36M	2.08M	1.66M	5.24M
Operating Income+	-19.79M	15.51M	11.85M	-8.01M	-25.88M	-8.82M	-11.79M	-21.8M	-8.84M	-17.25M
Operating Margin %	-0.04%	0.03%	0.02%	-0.01%	-0.16%	-0.09%	-0.11%	-0.21%	-0.07%	-0.13%
Operating Income Growth %	-2.07%	1.78%	-0.24%	-1.68%	-2.23%	0.66%	-0.34%	-0.85%	0.59%	-0.95%
EBITDA+	-10.72M	26.18M	23.82M	6.59M	-7.04M	11.04M	6.27M	-8.62M	-844K	-9.22M
EBITDA Margin %	-0.02%	0.05%	0.05%	0.01%	-0.04%	0.11%	0.06%	-0.08%	-0.01%	-0.07%
EBITDA Growth %	-1.42%	3.44%	-0.09%	-0.72%	-2.07%	2.57%	-0.43%	-2.37%	0.9%	-9.92%
D&A (Non-Cash Add-back)	9.07M	10.68M	11.97M	14.6M	18.84M	19.87M	18.06M	13.18M	8M	8.03M
EBIT	-16.86M	16M	13.59M	8.87M	-26M	-20.85M	-5.22M	-46.35M	27.6M	-16.84M
Net Interest Income+	-1.92M	-1.81M	-1.74M	-5.08M	-4.57M	-8.88M	-15.47M	-17.58M	-18.09M	-21.84M
Interest Income	71K	16K	211K	145K	72K	48K	81K	68K	0	0
Interest Expense	1.99M	1.83M	1.95M	5.23M	4.65M	8.93M	15.55M	17.65M	18.09M	21.84M
Other Income/Expense	934K	-493K	2.81M	-1.83M	-4.77M	-20.96M	-8.9M	-42.13M	18.36M	-21.43M
Pretax Income+	-18.85M	15.01M	16.4M	3.64M	-30.64M	-29.79M	-20.69M	-63.93M	9.51M	-38.67M
Pretax Margin %	-0.03%	0.03%	0.03%	0.01%	-0.19%	-0.3%	-0.19%	-0.62%	0.07%	-0.3%
Income Tax+	-7.4M	4.33M	-9.36M	1.52M	-8.77M	-6.35M	-5.21M	308K	183K	43K
Effective Tax Rate %	0.62%	0.71%	1.51%	0.58%	1.25%	1.08%	5.64%	1.56%	1.26%	1%
Net Income+	-11.64M	10.59M	24.83M	2.12M	-38.19M	-32.29M	-116.72M	-99.56M	12.01M	-38.72M
Net Margin %	-0.02%	0.02%	0.05%	0%	-0.24%	-0.32%	-1.05%	-0.96%	0.09%	-0.3%
Net Income Growth %	-1.86%	1.91%	1.34%	-0.91%	-19%	0.15%	-2.61%	0.15%	1.12%	-4.22%
Net Income (Continuing)	-11.99M	10.13M	25.76M	2.12M	-21.87M	-23.44M	-15.48M	-64.24M	9.33M	-38.72M
Discontinued Operations	0	542K	0	0	-16.32M	-8.86M	-101.24M	-35.33M	2.68M	0
Minority Interest	1.62M	1.54M	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.43	0.38	0.89	0.07	-1.31	-1.12	-3.97	-3.32	0.33	-1.27
EPS Growth %	-1.86%	1.88%	1.34%	-0.92%	-18.65%	0.15%	-2.54%	0.16%	1.1%	-4.85%
EPS (Basic)	-0.43	0.39	0.90	0.07	-1.31	-1.12	-3.97	-3.32	0.39	-1.27
Diluted Shares Outstanding	27.15M	27.65M	27.91M	28.61M	29.16M	29.29M	29.47M	29.96M	36.66M	34.82M
Basic Shares Outstanding	27.04M	27.5M	27.7M	28.36M	29.16M	29.29M	29.47M	29.96M	30.47M	34.82M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	May 2016	May 2017	May 2018	May 2019	May 2020	May 2021	May 2022	May 2023	May 2024	May 2025
Total Current Assets+	86.48M	81.28M	97.06M	133.04M	157.11M	148.32M	116.67M	93.88M	81.03M	85.68M
Cash & Short-Term Investments	9.89M	5.41M	2.9M	1.08M	360K	1.16M	991K	19.09M	8.46M	8.27M
Cash Only	9.89M	5.41M	2.9M	1.08M	360K	1.16M	991K	19.09M	8.46M	8.27M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	46.41M	45.9M	53.88M	69.56M	76.21M	41.43M	38.31M	29.02M	31.15M	43.67M
Days Sales Outstanding	31.3	31.48	37.51	45.54	173.77	149.91	125.68	102.58	88.65	123.68
Inventory	25.54M	25.29M	31.82M	54.13M	66.31M	63.08M	36M	40.84M	39.98M	32.29M
Days Inventory Outstanding	19.82	20.56	26.05	41.46	200.56	371.71	181.98	198.01	168.87	133.07
Other Current Assets	0	2.27M	3.21M	0	0	37.62M	34.31M	4.92M	1.44M	1.45M
Total Non-Current Assets+	256.99M	276.73M	307.64M	386.05M	384.21M	354.6M	158.03M	159.67M	172.93M	153.66M
Property, Plant & Equipment	120.88M	133.22M	159.62M	200.03M	217.66M	137.38M	124.22M	138.67M	149.16M	129.01M
Fixed Asset Turnover	4.48x	4.00x	3.28x	2.79x	0.74x	0.73x	0.90x	0.74x	0.86x	1.00x
Goodwill	49.62M	54.78M	54.51M	76.74M	69.39M	33.92M	13.88M	13.88M	13.88M	13.88M
Intangible Assets	21.4M	22.81M	21.84M	45.25M	38.1M	25.63M	4.2M	4.2M	4.2M	4.2M
Long-Term Investments	62.7M	63.6M	66.5M	61.1M	56.9M	45.1M	0	0	0	0
Other Non-Current Assets	-4.06M	-5.51M	-581K	-9.74M	-25.3M	112.57M	15.73M	2.92M	5.68M	6.58M
Total Assets+	343.47M	358.01M	404.7M	519.09M	541.31M	502.92M	274.7M	253.54M	253.96M	239.34M
Asset Turnover	1.58x	1.49x	1.30x	1.07x	0.30x	0.20x	0.41x	0.41x	0.51x	0.54x
Asset Growth %	-0.01%	0.04%	0.13%	0.28%	0.04%	-0.07%	-0.45%	-0.08%	0%	-0.06%
Total Current Liabilities+	56.52M	51.45M	88.38M	137.09M	164.39M	101.89M	176.58M	39.29M	38.87M	30.18M
Accounts Payable	30.9M	24.53M	34.67M	53.97M	51.65M	16.3M	12.95M	22.1M	16.33M	8.22M
Days Payables Outstanding	23.99	19.94	28.38	41.34	156.21	96.05	65.47	107.13	68.99	33.88
Short-Term Debt	11.37M	7.94M	31.94M	61.79M	88.95M	29M	138.18M	580K	943K	3.44M
Deferred Revenue (Current)	832K	310K	1000K	499K	352K	637K	919K	1000K	1000K	1000K
Other Current Liabilities	7.77M	11.17M	10.44M	10.04M	9.03M	50.4M	13.69M	4.14M	8.54M	8.31M
Current Ratio	1.53x	1.58x	1.10x	0.97x	0.96x	1.46x	0.66x	2.39x	2.08x	2.84x
Quick Ratio	1.08x	1.09x	0.74x	0.58x	0.55x	0.84x	0.46x	1.35x	1.06x	1.77x
Cash Conversion Cycle	27.14	32.1	35.18	45.66	218.13	425.58	242.19	193.46	188.53	222.88
Total Non-Current Liabilities+	74.6M	78.4M	63.77M	111.86M	145.88M	198.25M	10.3M	218.49M	203.77M	207.83M
Long-Term Debt	45.97M	42.3M	37.36M	87.67M	101.36M	164.9M	97.58M	101.06M	123.72M	127M
Capital Lease Obligations	3.8M	3.64M	3.64M	3.53M	26.38M	20.36M	7.66M	9.71M	4.94M	0
Deferred Tax Liabilities	22.44M	24.58M	17.48M	19.39M	13.59M	6.14M	126K	380K	543K	0
Other Non-Current Liabilities	1.74M	7.88M	5.28M	20.65M	4.55M	6.85M	-95.06M	104.39M	69.86M	80.83M
Total Liabilities	131.12M	129.86M	152.14M	248.95M	310.27M	300.14M	186.88M	257.77M	242.65M	238.01M
Total Debt+	61.97M	53.97M	72.94M	152.52M	221.12M	215.86M	247.78M	112.62M	133.57M	130.82M
Net Debt	52.07M	48.56M	70.04M	151.44M	220.76M	214.7M	246.79M	93.53M	125.11M	122.56M
Debt / Equity	0.29x	0.24x	0.29x	0.56x	0.96x	1.06x	2.82x	-	11.81x	97.92x
Debt / EBITDA	-	2.06x	3.06x	23.14x	-	19.55x	39.52x	-	-	-
Net Debt / EBITDA	-	1.85x	2.94x	22.98x	-	19.44x	39.36x	-	-	-
Interest Coverage	-9.96x	8.49x	6.08x	-1.53x	-5.57x	-0.99x	-0.76x	-1.23x	-0.49x	-0.79x
Total Equity+	212.35M	228.15M	252.56M	270.14M	231.04M	202.78M	87.82M	-4.23M	11.31M	1.34M
Equity Growth %	-0.04%	0.07%	0.11%	0.07%	-0.14%	-0.12%	-0.57%	-1.05%	3.67%	-0.88%
Book Value per Share	7.82	8.25	9.05	9.44	7.92	6.92	2.98	-0.14	0.31	0.04
Total Shareholders' Equity	210.73M	226.61M	252.56M	270.14M	231.04M	202.78M	87.82M	-4.23M	11.31M	1.34M
Common Stock	27K	27K	28K	29K	29K	29K	30K	30K	31K	37K
Retained Earnings	73.46M	84.47M	109.3M	109.71M	71.25M	38.58M	-78.97M	-178.54M	-166.52M	-205.24M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	432K	1.15M	64K	-2.81M	-1.36M	-586K	0	0	0
Minority Interest	1.62M	1.54M	0	0	0	0	0	0	0	0

Cash Flow

	May 2016	May 2017	May 2018	May 2019	May 2020	May 2021	May 2022	May 2023	May 2024	May 2025
Cash from Operations+	21.78M	29.33M	19.78M	16.02M	-17.04M	16.47M	-22.59M	-17.44M	257K	-206K
Operating CF Margin %	0.04%	0.06%	0.04%	0.03%	-0.11%	0.16%	-0.2%	-0.17%	0%	-0%
Operating CF Growth %	-0.17%	0.35%	-0.33%	-0.19%	-2.06%	1.97%	-2.37%	0.23%	1.01%	-1.8%
Net Income	-11.45M	10.68M	24.92M	411K	-15.15M	-32.29M	-116.72M	-99.56M	12.01M	-38.72M
Depreciation & Amortization	9.39M	10.68M	12.41M	15.23M	18.84M	19.87M	18.06M	13.18M	7.95M	8.03M
Stock-Based Compensation	3.46M	3.96M	4.4M	3.56M	2.38K	3.36M	2.61M	3.61M	6.2M	10.16M
Deferred Taxes	-9.94M	2.51M	-7.22M	910K	-5.44M	-7.87M	-6.83M	357K	163K	0
Other Non-Cash Items	32.85M	919K	-4.64M	-2.91M	12.37M	23.65M	83.38M	45.19M	-22.38M	25.02M
Working Capital Changes	-2.54M	584K	-10.1M	-1.18M	-27.66M	9.76M	-3.1M	19.79M	-3.7M	-4.7M
Change in Receivables	73K	-336K	-7.31M	-8.86M	-6.64M	5.78M	-6.14M	10.82M	-2.39M	-2.26M
Change in Inventory	-508K	855K	-6.53M	-10.93M	-12.18M	-2.82M	-2.18M	-14.81M	862K	7.69M
Change in Payables	-4.11M	-5.19M	4.96M	19.12M	-1.25M	-5.98M	9.34M	16.04M	-6.68M	-1.67M
Cash from Investing+	-41.59M	-25.01M	-35.59M	-96.8M	-23.89M	-12.31M	79.96M	-4.81M	-18.39M	-6.42M
Capital Expenditures	-40.87M	-22.59M	-33.59M	-44.73M	-26.69M	-25.22M	-29.94M	-21.48M	-18.39M	-13.41M
CapEx % of Revenue	0.08%	0.04%	0.06%	0.08%	0.17%	0.25%	0.27%	0.21%	0.14%	0.1%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-723K	81K	-2M	545K	364K	12.91M	-8.7M	0	0	0
Cash from Financing+	15.57M	-8.8M	13.29M	79.03M	40.02M	-3.42M	-57.02M	39.7M	7.51M	6.42M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-495K	-874K	-5.69M	23.79M	-1.79M	-10.89M	-1.61M	-6.32M	5.34M	1.13M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-19.08M	6.74M	-13.81M	-28.71M	-43.73M	-8.75M	-52.53M	-38.92M	-18.14M	-13.62M
FCF Margin %	-0.04%	0.01%	-0.03%	-0.05%	-0.27%	-0.09%	-0.47%	-0.38%	-0.14%	-0.11%
FCF Growth %	-3.21%	1.35%	-3.05%	-1.08%	-0.52%	0.8%	-5%	0.26%	0.53%	0.25%
FCF per Share	-0.70	0.24	-0.49	-1.00	-1.50	-0.30	-1.78	-1.30	-0.49	-0.39
FCF Conversion (FCF/Net Income)	-1.87x	2.77x	0.80x	7.55x	0.45x	-0.51x	0.19x	0.18x	0.02x	0.01x
Interest Paid	2.02M	2.33M	2.29M	0	0	13.22M	16.89M	31.02M	2.73M	1.91M
Taxes Paid	2.63M	2.79M	283K	0	0	0	441K	23K	72K	46K

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-5.38%	4.81%	10.33%	0.81%	-15.24%	-14.89%	-80.33%	-238.21%	339.11%	-612.08%
Return on Invested Capital (ROIC)	-5.79%	4.3%	2.97%	-1.61%	-4.44%	-1.52%	-2.35%	-7.71%	-5.88%	-9.94%
Gross Margin	13.11%	15.63%	14.94%	14.53%	24.61%	38.6%	35.11%	27.1%	32.63%	31.27%
Net Margin	-2.15%	1.99%	4.74%	0.38%	-23.86%	-32.01%	-104.89%	-96.41%	9.37%	-30.04%
Debt / Equity	0.29x	0.24x	0.29x	0.56x	0.96x	1.06x	2.82x	-	11.81x	97.92x
Interest Coverage	-9.96x	8.49x	6.08x	-1.53x	-5.57x	-0.99x	-0.76x	-1.23x	-0.49x	-0.79x
FCF Conversion	-1.87x	2.77x	0.80x	7.55x	0.45x	-0.51x	0.19x	0.18x	0.02x	0.01x
Revenue Growth	0.34%	-1.63%	-1.51%	6.36%	-71.29%	-36.98%	10.31%	-7.19%	24.2%	0.47%

Frequently Asked Questions

Growth & Financials

Lifecore Biomedical, Inc. (LFCR) reported $135.3M in revenue for fiscal year 2025. This represents a 57% decrease from $317.6M in 2012.

Lifecore Biomedical, Inc. (LFCR) grew revenue by 0.5% over the past year. Growth has been modest.

Lifecore Biomedical, Inc. (LFCR) reported a net loss of $32.5M for fiscal year 2025.

Dividend & Returns

Lifecore Biomedical, Inc. (LFCR) has a return on equity (ROE) of -612.1%. Negative ROE indicates the company is unprofitable.

Lifecore Biomedical, Inc. (LFCR) had negative free cash flow of $9.6M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

Lifecore Biomedical, Inc. (LFCR) 10-Year Financial Performance & Capital Metrics

LFCR • • Industrial / General

HealthcareSpecialty & Generic PharmaContract Manufacturing & APICDMO Services

Revenue $129M +0.5%
EBITDA -$9M -992.2%
Net Income -$39M -422.3%
EPS (Diluted) -1.27 -484.8%
Gross Margin 31.27% -4.2%
EBITDA Margin -7.15% -987.1%
Operating Margin -13.38% -94.1%
Net Margin -30.04% -420.8%
ROE -612.08% -280.5%
ROIC -9.94% -69.1%
Debt/Equity 97.92 +729.5%
Interest Coverage -0.79 -61.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 5.0% through buybacks

✗Weaknesses

✗High debt to equity ratio of 97.9x
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Expensive at 211.1x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-13.34%

5Y-4.24%

3Y5.02%

TTM5.31%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-596.83%

EPS CAGR

10Y-

5Y-

3Y-

TTM-1875.5%

ROCE

10Y Avg-4.01%

5Y Avg-6.64%

3Y Avg-8.73%

Latest-8.13%

Peer Comparison

CDMO Services

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
LFCRLifecore Biomedical, Inc.	303.48M	8.10	-6.38	0.47%	-24.01%	-88.29%		97.92
EVOEvotec SE	1.29B	3.62	-6.46	1.99%	-21.02%	-19.87%		0.47

Profit & Loss

	May 2016	May 2017	May 2018	May 2019	May 2020	May 2021	May 2022	May 2023	May 2024	May 2025
Sales/Revenue+	541.1M	532.26M	524.23M	557.56M	160.07M	100.87M	111.27M	103.27M	128.26M	128.87M
Revenue Growth %	0%	-0.02%	-0.02%	0.06%	-0.71%	-0.37%	0.1%	-0.07%	0.24%	0%
Cost of Goods Sold+	470.14M	449.07M	445.89M	476.56M	120.68M	61.94M	72.2M	75.28M	86.41M	88.57M
COGS % of Revenue	0.87%	0.84%	0.85%	0.85%	0.75%	0.61%	0.65%	0.73%	0.67%	0.69%
Gross Profit+	70.96M	83.19M	78.34M	81M	39.39M	38.94M	39.07M	27.98M	41.85M	40.3M
Gross Margin %	0.13%	0.16%	0.15%	0.15%	0.25%	0.39%	0.35%	0.27%	0.33%	0.31%
Gross Profit Growth %	0.08%	0.17%	-0.06%	0.03%	-0.51%	-0.01%	0%	-0.28%	0.5%	-0.04%
Operating Expenses+	56.74M	67.68M	64.75M	75.53M	65.26M	47.76M	50.86M	49.78M	50.69M	57.54M
OpEx % of Revenue	0.1%	0.13%	0.12%	0.14%	0.41%	0.47%	0.46%	0.48%	0.4%	0.45%
Selling, General & Admin	49.52M	58.21M	51.95M	64.06M	40.67M	27.72M	34.66M	38.97M	40.46M	44.05M
SG&A % of Revenue	0.09%	0.11%	0.1%	0.11%	0.25%	0.27%	0.31%	0.38%	0.32%	0.34%
Research & Development	7.23M	9.47M	12.8M	11.47M	7.58M	6.68M	7.84M	8.74M	8.57M	8.26M
R&D % of Revenue	0.01%	0.02%	0.02%	0.02%	0.05%	0.07%	0.07%	0.08%	0.07%	0.06%
Other Operating Expenses	0	-333K	0	0	17.01M	13.36M	8.36M	2.08M	1.66M	5.24M
Operating Income+	-19.79M	15.51M	11.85M	-8.01M	-25.88M	-8.82M	-11.79M	-21.8M	-8.84M	-17.25M
Operating Margin %	-0.04%	0.03%	0.02%	-0.01%	-0.16%	-0.09%	-0.11%	-0.21%	-0.07%	-0.13%
Operating Income Growth %	-2.07%	1.78%	-0.24%	-1.68%	-2.23%	0.66%	-0.34%	-0.85%	0.59%	-0.95%
EBITDA+	-10.72M	26.18M	23.82M	6.59M	-7.04M	11.04M	6.27M	-8.62M	-844K	-9.22M
EBITDA Margin %	-0.02%	0.05%	0.05%	0.01%	-0.04%	0.11%	0.06%	-0.08%	-0.01%	-0.07%
EBITDA Growth %	-1.42%	3.44%	-0.09%	-0.72%	-2.07%	2.57%	-0.43%	-2.37%	0.9%	-9.92%
D&A (Non-Cash Add-back)	9.07M	10.68M	11.97M	14.6M	18.84M	19.87M	18.06M	13.18M	8M	8.03M
EBIT	-16.86M	16M	13.59M	8.87M	-26M	-20.85M	-5.22M	-46.35M	27.6M	-16.84M
Net Interest Income+	-1.92M	-1.81M	-1.74M	-5.08M	-4.57M	-8.88M	-15.47M	-17.58M	-18.09M	-21.84M
Interest Income	71K	16K	211K	145K	72K	48K	81K	68K	0	0
Interest Expense	1.99M	1.83M	1.95M	5.23M	4.65M	8.93M	15.55M	17.65M	18.09M	21.84M
Other Income/Expense	934K	-493K	2.81M	-1.83M	-4.77M	-20.96M	-8.9M	-42.13M	18.36M	-21.43M
Pretax Income+	-18.85M	15.01M	16.4M	3.64M	-30.64M	-29.79M	-20.69M	-63.93M	9.51M	-38.67M
Pretax Margin %	-0.03%	0.03%	0.03%	0.01%	-0.19%	-0.3%	-0.19%	-0.62%	0.07%	-0.3%
Income Tax+	-7.4M	4.33M	-9.36M	1.52M	-8.77M	-6.35M	-5.21M	308K	183K	43K
Effective Tax Rate %	0.62%	0.71%	1.51%	0.58%	1.25%	1.08%	5.64%	1.56%	1.26%	1%
Net Income+	-11.64M	10.59M	24.83M	2.12M	-38.19M	-32.29M	-116.72M	-99.56M	12.01M	-38.72M
Net Margin %	-0.02%	0.02%	0.05%	0%	-0.24%	-0.32%	-1.05%	-0.96%	0.09%	-0.3%
Net Income Growth %	-1.86%	1.91%	1.34%	-0.91%	-19%	0.15%	-2.61%	0.15%	1.12%	-4.22%
Net Income (Continuing)	-11.99M	10.13M	25.76M	2.12M	-21.87M	-23.44M	-15.48M	-64.24M	9.33M	-38.72M
Discontinued Operations	0	542K	0	0	-16.32M	-8.86M	-101.24M	-35.33M	2.68M	0
Minority Interest	1.62M	1.54M	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.43	0.38	0.89	0.07	-1.31	-1.12	-3.97	-3.32	0.33	-1.27
EPS Growth %	-1.86%	1.88%	1.34%	-0.92%	-18.65%	0.15%	-2.54%	0.16%	1.1%	-4.85%
EPS (Basic)	-0.43	0.39	0.90	0.07	-1.31	-1.12	-3.97	-3.32	0.39	-1.27
Diluted Shares Outstanding	27.15M	27.65M	27.91M	28.61M	29.16M	29.29M	29.47M	29.96M	36.66M	34.82M
Basic Shares Outstanding	27.04M	27.5M	27.7M	28.36M	29.16M	29.29M	29.47M	29.96M	30.47M	34.82M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	May 2016	May 2017	May 2018	May 2019	May 2020	May 2021	May 2022	May 2023	May 2024	May 2025
Total Current Assets+	86.48M	81.28M	97.06M	133.04M	157.11M	148.32M	116.67M	93.88M	81.03M	85.68M
Cash & Short-Term Investments	9.89M	5.41M	2.9M	1.08M	360K	1.16M	991K	19.09M	8.46M	8.27M
Cash Only	9.89M	5.41M	2.9M	1.08M	360K	1.16M	991K	19.09M	8.46M	8.27M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	46.41M	45.9M	53.88M	69.56M	76.21M	41.43M	38.31M	29.02M	31.15M	43.67M
Days Sales Outstanding	31.3	31.48	37.51	45.54	173.77	149.91	125.68	102.58	88.65	123.68
Inventory	25.54M	25.29M	31.82M	54.13M	66.31M	63.08M	36M	40.84M	39.98M	32.29M
Days Inventory Outstanding	19.82	20.56	26.05	41.46	200.56	371.71	181.98	198.01	168.87	133.07
Other Current Assets	0	2.27M	3.21M	0	0	37.62M	34.31M	4.92M	1.44M	1.45M
Total Non-Current Assets+	256.99M	276.73M	307.64M	386.05M	384.21M	354.6M	158.03M	159.67M	172.93M	153.66M
Property, Plant & Equipment	120.88M	133.22M	159.62M	200.03M	217.66M	137.38M	124.22M	138.67M	149.16M	129.01M
Fixed Asset Turnover	4.48x	4.00x	3.28x	2.79x	0.74x	0.73x	0.90x	0.74x	0.86x	1.00x
Goodwill	49.62M	54.78M	54.51M	76.74M	69.39M	33.92M	13.88M	13.88M	13.88M	13.88M
Intangible Assets	21.4M	22.81M	21.84M	45.25M	38.1M	25.63M	4.2M	4.2M	4.2M	4.2M
Long-Term Investments	62.7M	63.6M	66.5M	61.1M	56.9M	45.1M	0	0	0	0
Other Non-Current Assets	-4.06M	-5.51M	-581K	-9.74M	-25.3M	112.57M	15.73M	2.92M	5.68M	6.58M
Total Assets+	343.47M	358.01M	404.7M	519.09M	541.31M	502.92M	274.7M	253.54M	253.96M	239.34M
Asset Turnover	1.58x	1.49x	1.30x	1.07x	0.30x	0.20x	0.41x	0.41x	0.51x	0.54x
Asset Growth %	-0.01%	0.04%	0.13%	0.28%	0.04%	-0.07%	-0.45%	-0.08%	0%	-0.06%
Total Current Liabilities+	56.52M	51.45M	88.38M	137.09M	164.39M	101.89M	176.58M	39.29M	38.87M	30.18M
Accounts Payable	30.9M	24.53M	34.67M	53.97M	51.65M	16.3M	12.95M	22.1M	16.33M	8.22M
Days Payables Outstanding	23.99	19.94	28.38	41.34	156.21	96.05	65.47	107.13	68.99	33.88
Short-Term Debt	11.37M	7.94M	31.94M	61.79M	88.95M	29M	138.18M	580K	943K	3.44M
Deferred Revenue (Current)	832K	310K	1000K	499K	352K	637K	919K	1000K	1000K	1000K
Other Current Liabilities	7.77M	11.17M	10.44M	10.04M	9.03M	50.4M	13.69M	4.14M	8.54M	8.31M
Current Ratio	1.53x	1.58x	1.10x	0.97x	0.96x	1.46x	0.66x	2.39x	2.08x	2.84x
Quick Ratio	1.08x	1.09x	0.74x	0.58x	0.55x	0.84x	0.46x	1.35x	1.06x	1.77x
Cash Conversion Cycle	27.14	32.1	35.18	45.66	218.13	425.58	242.19	193.46	188.53	222.88
Total Non-Current Liabilities+	74.6M	78.4M	63.77M	111.86M	145.88M	198.25M	10.3M	218.49M	203.77M	207.83M
Long-Term Debt	45.97M	42.3M	37.36M	87.67M	101.36M	164.9M	97.58M	101.06M	123.72M	127M
Capital Lease Obligations	3.8M	3.64M	3.64M	3.53M	26.38M	20.36M	7.66M	9.71M	4.94M	0
Deferred Tax Liabilities	22.44M	24.58M	17.48M	19.39M	13.59M	6.14M	126K	380K	543K	0
Other Non-Current Liabilities	1.74M	7.88M	5.28M	20.65M	4.55M	6.85M	-95.06M	104.39M	69.86M	80.83M
Total Liabilities	131.12M	129.86M	152.14M	248.95M	310.27M	300.14M	186.88M	257.77M	242.65M	238.01M
Total Debt+	61.97M	53.97M	72.94M	152.52M	221.12M	215.86M	247.78M	112.62M	133.57M	130.82M
Net Debt	52.07M	48.56M	70.04M	151.44M	220.76M	214.7M	246.79M	93.53M	125.11M	122.56M
Debt / Equity	0.29x	0.24x	0.29x	0.56x	0.96x	1.06x	2.82x	-	11.81x	97.92x
Debt / EBITDA	-	2.06x	3.06x	23.14x	-	19.55x	39.52x	-	-	-
Net Debt / EBITDA	-	1.85x	2.94x	22.98x	-	19.44x	39.36x	-	-	-
Interest Coverage	-9.96x	8.49x	6.08x	-1.53x	-5.57x	-0.99x	-0.76x	-1.23x	-0.49x	-0.79x
Total Equity+	212.35M	228.15M	252.56M	270.14M	231.04M	202.78M	87.82M	-4.23M	11.31M	1.34M
Equity Growth %	-0.04%	0.07%	0.11%	0.07%	-0.14%	-0.12%	-0.57%	-1.05%	3.67%	-0.88%
Book Value per Share	7.82	8.25	9.05	9.44	7.92	6.92	2.98	-0.14	0.31	0.04
Total Shareholders' Equity	210.73M	226.61M	252.56M	270.14M	231.04M	202.78M	87.82M	-4.23M	11.31M	1.34M
Common Stock	27K	27K	28K	29K	29K	29K	30K	30K	31K	37K
Retained Earnings	73.46M	84.47M	109.3M	109.71M	71.25M	38.58M	-78.97M	-178.54M	-166.52M	-205.24M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	432K	1.15M	64K	-2.81M	-1.36M	-586K	0	0	0
Minority Interest	1.62M	1.54M	0	0	0	0	0	0	0	0

Cash Flow

	May 2016	May 2017	May 2018	May 2019	May 2020	May 2021	May 2022	May 2023	May 2024	May 2025
Cash from Operations+	21.78M	29.33M	19.78M	16.02M	-17.04M	16.47M	-22.59M	-17.44M	257K	-206K
Operating CF Margin %	0.04%	0.06%	0.04%	0.03%	-0.11%	0.16%	-0.2%	-0.17%	0%	-0%
Operating CF Growth %	-0.17%	0.35%	-0.33%	-0.19%	-2.06%	1.97%	-2.37%	0.23%	1.01%	-1.8%
Net Income	-11.45M	10.68M	24.92M	411K	-15.15M	-32.29M	-116.72M	-99.56M	12.01M	-38.72M
Depreciation & Amortization	9.39M	10.68M	12.41M	15.23M	18.84M	19.87M	18.06M	13.18M	7.95M	8.03M
Stock-Based Compensation	3.46M	3.96M	4.4M	3.56M	2.38K	3.36M	2.61M	3.61M	6.2M	10.16M
Deferred Taxes	-9.94M	2.51M	-7.22M	910K	-5.44M	-7.87M	-6.83M	357K	163K	0
Other Non-Cash Items	32.85M	919K	-4.64M	-2.91M	12.37M	23.65M	83.38M	45.19M	-22.38M	25.02M
Working Capital Changes	-2.54M	584K	-10.1M	-1.18M	-27.66M	9.76M	-3.1M	19.79M	-3.7M	-4.7M
Change in Receivables	73K	-336K	-7.31M	-8.86M	-6.64M	5.78M	-6.14M	10.82M	-2.39M	-2.26M
Change in Inventory	-508K	855K	-6.53M	-10.93M	-12.18M	-2.82M	-2.18M	-14.81M	862K	7.69M
Change in Payables	-4.11M	-5.19M	4.96M	19.12M	-1.25M	-5.98M	9.34M	16.04M	-6.68M	-1.67M
Cash from Investing+	-41.59M	-25.01M	-35.59M	-96.8M	-23.89M	-12.31M	79.96M	-4.81M	-18.39M	-6.42M
Capital Expenditures	-40.87M	-22.59M	-33.59M	-44.73M	-26.69M	-25.22M	-29.94M	-21.48M	-18.39M	-13.41M
CapEx % of Revenue	0.08%	0.04%	0.06%	0.08%	0.17%	0.25%	0.27%	0.21%	0.14%	0.1%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-723K	81K	-2M	545K	364K	12.91M	-8.7M	0	0	0
Cash from Financing+	15.57M	-8.8M	13.29M	79.03M	40.02M	-3.42M	-57.02M	39.7M	7.51M	6.42M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-495K	-874K	-5.69M	23.79M	-1.79M	-10.89M	-1.61M	-6.32M	5.34M	1.13M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-19.08M	6.74M	-13.81M	-28.71M	-43.73M	-8.75M	-52.53M	-38.92M	-18.14M	-13.62M
FCF Margin %	-0.04%	0.01%	-0.03%	-0.05%	-0.27%	-0.09%	-0.47%	-0.38%	-0.14%	-0.11%
FCF Growth %	-3.21%	1.35%	-3.05%	-1.08%	-0.52%	0.8%	-5%	0.26%	0.53%	0.25%
FCF per Share	-0.70	0.24	-0.49	-1.00	-1.50	-0.30	-1.78	-1.30	-0.49	-0.39
FCF Conversion (FCF/Net Income)	-1.87x	2.77x	0.80x	7.55x	0.45x	-0.51x	0.19x	0.18x	0.02x	0.01x
Interest Paid	2.02M	2.33M	2.29M	0	0	13.22M	16.89M	31.02M	2.73M	1.91M
Taxes Paid	2.63M	2.79M	283K	0	0	0	441K	23K	72K	46K

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-5.38%	4.81%	10.33%	0.81%	-15.24%	-14.89%	-80.33%	-238.21%	339.11%	-612.08%
Return on Invested Capital (ROIC)	-5.79%	4.3%	2.97%	-1.61%	-4.44%	-1.52%	-2.35%	-7.71%	-5.88%	-9.94%
Gross Margin	13.11%	15.63%	14.94%	14.53%	24.61%	38.6%	35.11%	27.1%	32.63%	31.27%
Net Margin	-2.15%	1.99%	4.74%	0.38%	-23.86%	-32.01%	-104.89%	-96.41%	9.37%	-30.04%
Debt / Equity	0.29x	0.24x	0.29x	0.56x	0.96x	1.06x	2.82x	-	11.81x	97.92x
Interest Coverage	-9.96x	8.49x	6.08x	-1.53x	-5.57x	-0.99x	-0.76x	-1.23x	-0.49x	-0.79x
FCF Conversion	-1.87x	2.77x	0.80x	7.55x	0.45x	-0.51x	0.19x	0.18x	0.02x	0.01x
Revenue Growth	0.34%	-1.63%	-1.51%	6.36%	-71.29%	-36.98%	10.31%	-7.19%	24.2%	0.47%

Frequently Asked Questions

Growth & Financials

Lifecore Biomedical, Inc. (LFCR) reported $135.3M in revenue for fiscal year 2025. This represents a 57% decrease from $317.6M in 2012.

Lifecore Biomedical, Inc. (LFCR) grew revenue by 0.5% over the past year. Growth has been modest.

Lifecore Biomedical, Inc. (LFCR) reported a net loss of $32.5M for fiscal year 2025.

Dividend & Returns

Lifecore Biomedical, Inc. (LFCR) has a return on equity (ROE) of -612.1%. Negative ROE indicates the company is unprofitable.

Lifecore Biomedical, Inc. (LFCR) had negative free cash flow of $9.6M in fiscal year 2025, likely due to heavy capital investments.